Therapeutic Response

Wild type ALK and Wild type EGFR status confers therapeutic sensitivity to Cisplatin in combination with Ipilimumab, Nivolumab, and Pemetrexed in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Opdivo (nivolumab) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.
Yervoy (ipilimumab) [product monograph]. HC. Health Canada approved ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.
Yervoy (ipilimumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.